Details on sensor calibration and calibration curve fitting
Calibration curves were made to cover a range of biomarker concentrations relevant for clinical serum specimens, as shown in Figure 3 of the manuscript. To conserve analysis time while avoiding possible interferences between antigens, calibrations were obtained simultaneously for CEA, ALCAM, AFP, and PSA. CA19-9 and CA15-3 calibrations were obtained together, but apart from the other antigens. By running a few concentration of CA15-3 with no CA19-9 and vice versa, it was possible to obtain corrections for how the stock antigen solutions interfered with each other. Similarly, osteopontin and CA-125 calibrations were run together, but apart from the other antigens. Each point on the calibration curve represents one measurement on one chip based on the net shift in resonance frequency (pm) obtained from the tertiary amplification step. Because the tertiary amplification step consisted of 6 mini-steps (anti-biotin, anti-PE, anti-biotin, anti-PE, anti-biotin, anti-PE), it was possible to use a different region of the tertiary amplification curve for each antigen. This was important because some of the antigens tended to generate higher signals and would saturate the tertiary signal faster than the antigens that generated lower signal. For example, the ALCAM calibration curve had the largest range of quantitation when the shift was measured after only one of the amplification mini-steps. At later steps of the amplification, the last two points on the calibration curve became indistinguishable from each other. In contrast, CA15-3 tended to display only small relative shifts, and thus using 6 amplification steps increased the signal that could be observed.
Further signal enhancement steps would have led to increased magnitudes of signal and lower limits of detection; however, this would consume additional reagents and time. Moreover, we empirically found that six steps of signal enhancement provided sufficient sensitivity for the biomarker screening efforts described herein. The number of amplification steps used for each antigen's calibration curve is given in Supplementary Table 1. The error bars shown on the calibration curves were derived using a 17% error or the standard deviation of the ring-to-ring measurements on a given chip, whichever was larger. The 17% value comes from measuring the chip-to-chip standard deviation for multiple 8-plex chips running the same assay. This same error formula was applied to the relative signal index measurements used in Figure 5 . Calibration parameters are listed in Supplementary Table 1 . The units for AFP, ALCAM, Osteopontin, CEA, and PSA are given in ng/mL whereas CA19-9, CA15-3, and CA125 are given in units/mL (U/mL). These labels are based on the units given from the commercially obtained antigen solutions. Supplementary Table 2 lists the results of the calibration analysis for individual tested serum samples with reference to the upper and lower quantitation limits for the calibration curves listed in Supplementary Table 6 . A "-" indicates a measurement that was below the range of quantitation used for the calibration curve. A result with a ">" indicates that the measurement fell higher than the quantitation range used for the calibration curve. CA-125 fell below the range of accurate quantitation in all samples, and so it is not listed on the table. A few of the samples still had measurable shifts even though the values fell below the range of quantitation. As a result, Figure 5 displays a relative index value for these antigens. This is a case of the limit of detection (LOD) being lower than the limit of quantitation (LOQ).
In Supplementary Table 2 the errors shows for each measurement are extrapolated from the standard deviation of the measurement signal via the calibration curve. In other words, y ± yerror is converted to x ± xerror, where yerror was determined using relative standard deviation, as described previously. Supplementary Table 1. Number of amplification steps used for the calibration curve, the upper and lower limits of quantitation used for these curves, and the fitting parameters for both the dose-response calibration curves as well as the linear calibration curves. 
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